Apr 10, 2002 (Pharmacy News
Related Results
RAMIPRIL.Sandoz launches ramiprilCutaneous vasculitis secondary to ramiprilRamipril cuts diabetes riskRamipril-associated hepatotoxicity
ABIX via COMTEX) -…
This study is currently recruiting patients. Verified and sponsored by Sanofi-Aventis. The present study is designed to evaluate the hypothesis that the Angiotensin Converting Enzyme (ACE) inhibitor Ramipril improves vascular function and reduces markers of low-grade chronic inflammation and oxidative stress in patients with rheumato…
High blood pressure (also called hypertension) is a life-threatening condition that affects 1 in every 4 Americans over age 18. Anyone can get it, and as you get older, the odds of your developing it increase, especially if you are overweight …
BRISTOL, Tenn. — King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues were $492 million during the third quarter ended September 30, 2006, compared to $518 million in the third quarter of 2005. Including special items, net earnings equaled $90 million and diluted earnings per share equaled $0.37 during the third quarter ended September 30, 2006, compared to net income of $122 million and diluted earnings per share of $0.50 in the sa…
CHICAGO — Zacks Equity Research highlights 51job (Nasdaq: JOBS) as the Bull of the Day and Hewitt Associates (NYSE: HEW) as the Bear of the Day. In addition, Zacks Equity Research provides analysis on King Pharmaceuticals (NYSE: KG) and Pride International (NYSE: …
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c32022) has announced the addition of Barriers to Effective Management of Metabolic Syndrome to their offering.
Business Implications
–Sedentary lifestyles and a steady increase in obesity have contributed to rapid growth in the prevalence of metabolic syndrome in many developed nations.We estimate that, in 2003, almost 123 million people had metabolic syndrome in …
